Navigation Links
Metabolic Solutions Development Company announces publication of data describing a new drug target for diabetes
Date:5/15/2013

41 percent increase over a five-year period.

"The only drug that attacks both insulin resistance and beta cell dysfunction, the root causes of type 2 diabetes, is an insulin sensitizer," said Ralph A. DeFronzo , M.D., professor of Medicine and Chief of the Diabetes Division at the University of Texas Health Science Center and the Audie L. Murphy Memorial VA Hospital in San Antonio, Texas. "There is a growing interest in a new generation of insulin sensitizers that appear to bind to proteins in the mTOT complex, but not activate the PPARg receptor at therapeutic doses. As such, these new therapeutic agents likely will not elicit the side effects associated with currently approved insulin sensitizers."

Previously, it was believed that both the activity and the side-effects of the only approved class of drugs used to treat insulin resistance, thiazolidinedione (TZD) insulin sensitizers, were mediated through PPARg.  It is now generally accepted that activating PPARg drives the side effects of this class of therapeutic agents (e.g., increased adiposity, volume expansion, bone loss and congestive heart failure), which has limited the use of current drugs and prevented the development of new insulin sensitizing agents.3  With the discovery of the mTOT complex, researchers now have a clear path forward to create new, more useful insulin sensitizers.

The mTOT discovery team is led by MSDC's co-founders, Jerry Colca, PhD and Rolf Kletzien, PhD, who were among the original researchers in the field of insulin sensitizers, and who selected and led the early development of Actos® (pioglitazone), a PPARg agonist.  MSDC scientists are utilizing their unique insight into the potential key role of the mTOT compl
'/>"/>

SOURCE Metabolic Solutions Development Company, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Metabolic Pathways Collection at SRI International the Largest in the World
2. Cardiometabolic Health Congress Expert Faculty Evaluate the Clinical Implications of Newly FDA-Approved Treatment for Homozygous Familial Hypercholesterolemia
3. Highly efficient production of advanced biofuel by metabolically engineered microorganism
4. Metabolic engineer synthesizes key breast milk ingredient, makes research possible
5. Profil Institute Continues to Publish New Findings in Metabolic Research
6. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference
7. GenoVive, a pioneer in DNA-based weight management solutions, today announced the companys first European partnership as of May 1, 2013 with DNADIETA based in Poland.
8. Integrated Service Solutions, Inc. Celebrates 15 Years in Business
9. BioLife Solutions Announces Record Revenue of $2.2 Million in First Quarter of 2013
10. Elissa Guerra Joins Pursuit as VP of Client Solutions
11. Challenges and Solutions in Conducting Biosimilar Trials, New Life Science Webinar Hosted by Xtalks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... 6 Memory Pharmaceuticals,Corp. (Nasdaq: MEMY ) today ... Business Development, will provide a company update at,the Rodman ... 2008 at 11:10 a.m. EST at the New York ... access the live webcast of the presentation by,visiting the ...
... PHOENIX, Nov. 6 NutraCea (OTC Bulletin Board:,NTRZ), ... nutrient research and,technology announced today that it has ... Financial Officer. Todd Crow, in accordance with,his previously ... remain,available in a consulting and advisory capacity., ...
... today at 5:00 p.m. Eastern to discuss ... recent business highlights -, SAN DIEGO, Calif., Nov. 6 ... focused on,the treatment of obesity and other central nervous system-related,disorders, ... ended September 30, 2008., Three Months Ended September 30, ...
Cached Biology Technology:NutraCea Appoints New Chief Financial Officer 2Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results 2Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results 3Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results 4Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results 5Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results 6Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results 7Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results 8Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results 9
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... N.H. Small streams play a significant role in ... by removing nitrogen before it ends up in estuaries ... the journal Nature. University of New Hampshire professor William ... department of natural resources, are among the co-authors of ...
... one of the worlds most endangered speciesa North Island brown ... been incubating the egg for five weeks, following a month ... signs of pipping: the process in which the chick starts ... isolet for four days and is now in a specially ...
... minimizing the amount of human-generated pollutants, such as nitrogen, ... excess nitrogen degrades lakes and coastal oceans by stimulating ... phenomenon, also known as eutrophication, threatens fisheries around the ... that included Cary Institute ecologists Dr. Stuart E.G. Findlay ...
Cached Biology News:Streams remove significant amounts of nitrogen, preventing downstream 'dead zones' 2Rare North Island brown kiwi hatches at the Smithsonian's National Zoo 2Small streams mitigate human influence on coastal ecosystems 2
FluoSpheres® biotin-labeled microspheres, 1.0 µm, yellow-green fluorescent (505/515) *1% solids*...
chk 1 kinase...
muscle actin (HUC1-1)...
... The Human Neural Stem Cell ... media supplements, which can be used ... expansion of NSCs and the induction ... oligodendrocyte lineages. An antibody panel consisting ...
Biology Products: